nvg-111
novalgen
['cll', 'nvg-111']
#noeticinsight is sharing the latest in phase i studies presented at #ash22 early data for a ror1 targeting bispecific t cell engager (nvg-111) shows promising tolerability, safety, and efficacy against r/r cll + mcl resistant to systemic therapies. 